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Edited by Felix WielandAbstract In the disease cystic ﬁbrosis (CF), the most common
mutation delF508 results in endoplasmic reticulum retention of
misfolded CF gene proteins (CFTR). We show that the a-1,2-
glucosidase inhibitor miglustat (N-butyldeoxynojirimycin, NB-
DNJ) prevents delF508-CFTR/calnexin interaction and restores
cAMP-activated chloride current in epithelial CF cells. More-
over, miglustat rescues a mature and functional delF508-CFTR
in the intestinal crypts of ileal mucosa from delF508 mice. Since
miglustat is an orally active orphan drug (Zavesca) prescribed
for the treatment of Gaucher disease, our ﬁndings provide the ba-
sis for future clinical evaluation of miglustat in CF patients.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The CFTR gene encodes the cystic ﬁbrosis transmembrane
conductance regulator (CFTR) that is mutated in the genetic
disorder cystic ﬁbrosis [1,2]. CFTR is an apical cAMP-acti-
vated Cl channel present in epithelial cells [3,4]. Most CF pa-
tients have the delF508 mutation leading to misfolding and
retardation of the protein in the endoplasmic reticulum (ER)
[4–6]. The ER quality control machinery monitors the folding
and assembly of proteins, ensuring that only folded proteins
proceed along the secretory pathway [7]. N-glycosylation al-
lows the interaction of newly synthesized glycoproteins with
the chaperone system in the ER [5,8,9]. The chaperone caln-
exin is a ER lectin-like protein binding monoglucosylated
oligosaccharides, i.e., N-linked glycans of the form Glc-
NAc2Man9Glc1 resulting from the removal of the two outer
glucoses by glucosidases [8–10]. Recent evidences suggest that
inhibitors of ER calcium pumps correct the delF508 traﬃcking
defect through partial inhibition of delF508-CFTR/calnexinAbbreviations: CF, cystic ﬁbrosis; CFTR, CF transmembrane conduc-
tance regulator; Cst, Castanospermine; ER, endoplasmic reticulum;
Isc, short-circuit current; NB-DNJ, N-butyldeoxynojirimycin; NB-
DGJ, N-butyldeoxygalactonojirimycin
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doi:10.1016/j.febslet.2006.03.010interaction [11,12]. Moreover, overexpression of calnexin leads
to greater stability of delF508 in the ER [13] and a truncated
form of calnexin partially reversed the misprocessing of func-
tional delF508-CFTR [14].
In the present study, we hypothesized that by inhibiting the
deglucosylation of delF508 protein in the ER, glucosidase
inhibitors might prevent the interaction of delF508-CFTR
with calnexin and hence its entry in the degradation pathway.
To test this hypothesis, we used miglustat an N-alkylated imi-
no sugar (N-butyldeoxynojirimycin, NB-DNJ) and castano-
spermine, inhibiting ER a-1,2-glucosidase, and one inactive
imino-sugar analogue (N-butyldeoxygalactonojirimycin, NB-
DGJ) [15,16].2. Materials and methods
2.1. Cells
Human nasal epithelial JME/CF15 [17], tracheal gland serous
CFKM4 [18] and pancreatic duct CFPAC-1 [19] cell lines were derived
from delF508 homozygous patients. Non-transfected CHO-K1, stably
transfected wt- and delF508-CHO cells and Cos-7 cells transiently
transfected with GFP-delF508-CFTR cDNA or GFP alone (denoted
Cos-7 mock) were used as described [20,21].
2.2. Immunoprecipitation and Western-blotting
CF15 cell lysates were incubated with monoclonal anti-human
CFTR antibody (2 lg, IgG2a clone 24-1, R&D Systems, USA) or
polyclonal rabbit anti-calnexin antibody (2 ll/ml, SPA-860, Stress-
gen, USA). Immunoblots were probed with monoclonal mouse
anti-CFTR antibody (10 lg/ml, IgG1 M3A7, Chemicon, USA), poly-
clonal rabbit anti-calnexin antibody (2 ll/ml, SPA-860) or mouse
anti-b tubulin antibody (1:200, Tebu-bio, USA). The protein levels
were expressed as densitometry and percentage of controls. Other
details [11].
2.3. Functional assay
Perforated whole-cell patch-clamp analysis was applied to CF15
cells. Patch electrodes (GC150-TF10, Harvard Apparatus, USA)
ﬁlled with intracellular solution (resistances of 3–4 MX) were con-
nected to the RK-400 ampliﬁer (Biologic, France) through an Ag/
AgCl pellet. External solution (mM): 145 NaCl, 4 CsCl, 1 MgCl2,
1 CaCl2, 5 D-glucose, 10 TES (pH 7.4, 315 mOsm). Intra-pipette
solution (mM): 113 L-aspartic acid, 113 CsOH, 27 CsCl, 1 NaCl,
1 EGTA, 1 MgCl2, 3 Mg-ATP (ex-temporane), 10 TES (pH 7.2 with
CsOH, 285 mOsm) and amphotericin B (100 lg/ml) renewed every
2 h. Only cells with input resistance 615 MX were analysed. The
mean access resistance and whole cell capacitance were
12 ± 0.6 MX and 35 ± 4.3 pF (n = 44). Currents were obtained in re-
sponse to voltage steps from 80 to +80 mV in 20 mV increment.
Data were collected using pClamp 6.0.3 package software (Axon
Instruments, USA).blished by Elsevier B.V. All rights reserved.
2082 C. Norez et al. / FEBS Letters 580 (2006) 2081–2086CFTR Cl channel activity was assayed on a cell population by the
iodide (125I) eﬄux technique as described [11]. All chemicals are from
Sigma Chemicals (St. Louis, MO) exept NB-DNJ and NB-DGJ (Tor-
onto Research Chemicals, Canada), forskolin and genistein (PKC
Pharmaceuticals, USA). CFTRinh–172 and TS-TM calix[4]arene were
provided by Dr. Bridges, University of Pittsburgh. Results are ex-
pressed as mean ± S.E.M. of n observations. Sets of data were com-
pared with Student’s t test using GraphPad Prism 4.0 (GraphPad
Software, USA). ns, non-signiﬁcant diﬀerence; *P < 0.05; **P < 0.01;
***P < 0.001.2.4. Ex vivo studies
Rotterdam delF508/delF508-CFTR mice (Cftrtm1Eur), their litter-
mate controls (FVB inbred, 14–17 weeks old, weight between 20 and
30 g, kept on solid food in a pathogen-free environment) and Cftr-
KO mice (Cftrtm2Cam) were used [22,23]. Muscle-stripped ileal mucosa
was incubated in William’s E-Glutamax medium supplemented withFig. 1. Miglustat prevents delF508-CFTR/calnexin interaction. (A) CFTR im
cells or not. Calnexin WB (lane 1) and non-immune mouse IgG (lane 2) wer
presented. From lanes 3 to 6 we compared IP CFTR/WB calnexin from cells i
incubated at 27 C (lane 4) to the control 37 C (lane 3). In the second exper
denoted Cst (lane 9) to the control 37 C (lane 7). The calnexin intensity band
control (i.e., 37 C: lane 3 for the ﬁrst gel and lane 7 for the second gel). Then
treatment except for castanospermine n = 2. (B) Calnexin and b-tubulin WB f
protein). Histograms show the b-tubulin/calnexin ratio density band (n = 3). (
CFTR WB in CHO-wt lysates (lane 1) and non-immune rabbit IgG IP (lane
CFTR band B intensity expressed in % of control (1 < n < 2). Treatments are
(control), low-temperature (24 h, 27 C), miglustat (2 h, 100 lM, 37 C), ca
100 lM, 37 C).insulin (10 lg/ml) and dexamethasone (20 lg/ml). At diﬀerent time
points, the compound was removed by repeated washings followed
by short-circuit current (Isc) measurements in mini-Ussing chambers
[24]. Western blotting was as described [25]. For immunohistochemis-
try, tissues were ﬁxed in 4% (wt/vol) paraformaldehyde. Sections
(5 lm) were stained with the antibody R3195 (1:500) as described [25].3. Results
3.1. Miglustat prevents delF508-CFTR/calnexin interaction in
CF15 cells
Analysis of CFTR immunoprecipitation on calnexin Wes-
tern blot showed that miglustat and castanospermine prevent,
by 75% and 50%, respectively, the delF508-CFTR/calnexin
interaction as compared to cells at 37 C, treated by NB-DGJmunoprecipitation (IP) on calnexin Western-blot (WB) in treated CF15
e used as positive and negative controls. Two separate experiments are
ncubated 2 h at 37 C with miglustat (lane 5), with NB-DGJ (lane 6) or
iment, lanes 7–9, we compared miglustat (lane 8) and castanospermine
for each experimental condition was expressed as function of its own IP
the histograms report the mean ± S.E.M. of these data; n = 5 for each
rom untreated (lane 1) and treated cell (lanes 2–5) lysates (50 lg of total
C) Calnexin IP on CFTRWB in cells treated (lanes 3–6) or not (lane 2).
7) were used as positive and negative controls. Bar graph reports the
indicated below each lane or bar with a positive sign. Treatment: 37 C
stanospermine denoted Cst (2 h, 100 lg/ml, 37 C) or NB-DGJ (2 h,
C. Norez et al. / FEBS Letters 580 (2006) 2081–2086 2083or maintained at 27 C, a procedure known to rescue delF508-
CFTR to the cell surface [26] (see Fig. 1A). Glucosidase inhib-
itors have no direct eﬀect on the production of calnexin itself
because the b-tubulin/calnexin ratio remains unchanged (see
Fig. 1B). Finally, the reverse co-immunoprecipitation (see
Fig. 1C) conﬁrms that delF508-CFTR and calnexin form a
complex in the ER prevented by miglustat and to a lesser ex-
tent by castanospermine.
3.2. Rescue of functional delF508-CFTR by miglustat
Perforated patch-clamp technique was applied to 37 C (see
Fig. 2A), low-temperature (see Fig. 2B), miglustat (see Fig. 2C)
or NB-DGJ-treated (see Fig. 2D) CF15 cells. Cl currents
were ﬁrst recorded in resting cells (see Fig. 2A–D, top traces)






Time (ms) Time (ms) Time (ms)
Time (ms) Time (ms) Time (ms)
Time (ms) Time (ms) Time (ms)
I (p
A)






















































































































































































































Fig. 2. Rescue of functional delF508-CFTR in miglustat-treated cells. (A)–(D
by low-temperature (B), miglustat (C), NB-DGJ (D) or untreated (A). Top
genistein. Bottom traces: stimulation by forskolin/genistein + glibenclamide. T
each series of experiments. Numbers of analyzed cells are indicated. The ba
eﬄux curves in 37 C, low-temperature-, miglustat-, castanospermine- or NB
genistein as indicated by the horizontal bar above the traces. Stimulation of m
glibenclamide, 500 lM DPC, 500 lM DIDS or 100 nM calixarene (F). n = 4
CFPAC-1, Cos7 GFP-delF508, Cos 7 mock, CHO-K1 and CHO delF508
Functional experiments with 37 C-, low-temperature- (24 h, 27 C), miglusta
37 C) or NB-DGJ- (2 h, 100 lM, 37 C) treated CF cells. Stimulation of CFD, middle traces). A linear non-voltage-dependent Cl current
was recorded only for cells cultured at 27 C or incubated with
miglustat (see Fig. 2B and C, middle traces). This current was
fully inhibited by glibenclamide (see Fig. 2B and C, bottom
traces). Untreated or NB-DGJ treated cells failed to respond
to forskolin/genistein (see Fig. 2A and D, middle traces).
The current densities measured at +40 mV with cells stimu-
lated were 0.9 ± 0.19 pA/pF (see Fig. 2A), 28.75 ± 3.2 pA/pF
(see Fig. 2B), 14.3 ± 1.05 pA/pF (see Fig. 2C) and
1.06 ± 0.03 pA/pF (see Fig. 2D).
Iodide eﬄux experiments performed in untreated or NB-
DGJ treated CF15 cells conﬁrm absence of response after for-
skolin/genistein stimulation (see Fig. 2E, top panel). On the
contrary, the bottom panel demonstrates stimulation of iodide










































































































































































































) Perforated whole-cell patch-clamp recordings with CF15 cells treated
traces: cells are unstimulated. Middle traces: stimulation by forskolin/
he corresponding current density/voltage relationships are given below
th contained calixarene (200 nM) and DIDS (200 lM). (E)–(F) Iodide
-DGJ-treated CF15 cells. Iodide eﬄuxes are stimulated by forskolin/
iglustat-treated CF15 cells in presence of 10 lMCFTRinh-172, 100 lM
for each condition. (G) Iodide eﬄux experiments with CF15, CFKM4,
cells treated as indicated below each bar with a positive sign (n = 4).
t- (2 h, 100 lM, 37 C), castanospermine denoted Cst (2 h, 100 lg/ml,
TR: forskolin (10 lM), genistein (30 lM).
Fig. 3. Cellular localization, maturation and functionality of delF508-CFTR protein in ileal mucosa from delF508 mice. (A)–(D) Ex vivo exposure of
ileal mucosa from delF508 mice to miglustat results in the appearance of CFTR protein (brown immunostaining) in the intestinal crypts. (A) WT
mice, untreated; (B) Cftr/ mice, untreated; (C) CftrdelF508/delF508 mice, PBS treated (4 h, 37 C); (D) CftrdelF508/delF508 mice, miglustat treated
(100 lM, 4 h, 37 C). Scale bars: 12 lm (left), 30 lm (right). (E) Rescue of forskolin/genistein-activated Cl current response (Isc) in ileal mucosa
from delF508-CFTR mice by miglustat (4 h, 100 lM). (top) Isc tracings showing the eﬀect of miglustat pretreatment on the response to forskolin
(10 lM) and genistein (100 lM) of delF508-CFTR vs. WT mice. (bottom) summary data from duplicate measurements on 8 delF508-CFTR mice;
delta Isc represents the combined response to forskolin + genistein; *P < 0.05, Student t-test. (F) Detection of core-glycosylated (band B) and mature
(band C) CFTR by western blotting in wt- and low-temperature- or miglustat-treated delF508 CFTR ileum.
2084 C. Norez et al. / FEBS Letters 580 (2006) 2081–2086treatments. Note the lower eﬃcacy of castanospermine vs.
miglustat. Stimulation of miglustat-treated cells was inhibited
by DPC, glibenclamide and CFTRinh-172 [27] but neither by
calixarene nor DIDS (Fig. 2F) as expected for CFTR [11].
The response to forskolin/genistein after treatment with miglu-
stat or NB-DGJ was analyzed in diﬀerent delF508-CFTR
expressing cell types. In all these cell types, a delF508-CFTR
dependent iodide eﬄux was rescued by miglustat to the same
level as cells cultured at 27 C (see Fig. 2G). Fig. 2G also
shows that miglustat has no eﬀect in CFTR-minus cells (e.g.,
parental CHO-K1 and mock Cos-7).3.3. Correction of abnormal processing and function of delF508-
CFTR in CftrdelF508/delF508 mice
We studied the eﬀect of miglustat in ileal tissues from
Cftr+/+, Cftr/ and CftrdelF508/delF508 mice. Immunostaining
study localized CFTR in apical membrane of intestinal crypt
cells of Cftr+/+ mice (see Fig. 3A). CFTR is absent in prep-
arations from Cftr/ mice (see Fig. 3B). On contrary of
ileal tissues from CftrdelF508/delF508 mice maintained in PBS
(see Fig. 3C), exposure to miglustat shows that delF508 pro-
teins have clearly moved to the apical membrane (see
Fig. 3D). However, the immunolocalization signal in intesti-
nal crypt cells diﬀers from Cftr+/+; the rescued protein is also
localized throughout the cell interior (see Fig. 3D). Ex vivo
exposure of intestinal mucosa from CftrdelF508/delF508 mice to
miglustat resulted in a threefold increase in forskolin/geni-
stein-stimulated current (see Fig. 3E), indicating restorationof transepithelial chloride secretion up to 55% of the secre-
tory response in Cftr+/+-mice (140 ± 26 lA/cm2, n = 28). This
gain in CFTR function is in good agreement with the
delF508-CFTR localization and was accompanied by an in-
crease (1.8-fold) in the band C/band B ratio as detected by
western blotting corresponding to 12% mature WT cftr
(Fig. 3F). Functional rescue of delF508 CFTR up to WT
levels by low-temperature incubation [28] is accompanied
by a gain in mature band C CFTR protein expression from
4% to 25% of WT.4. Discussion
Our data show a relatively fast rescue of functional delF508-
CFTR by miglustat in human and mice epithelial cells. Miglu-
stat prevents the delF508-CFTR/calnexin interaction in the
ER suggesting that inhibition of deglucosylation of nascent
proteins may be the molecular mechanism of the miglustat ef-
fect. Importantly, inhibition of N-linked oligosaccharide trim-
ming by the glucosidase inhibitors 1-deoxynojirimycin and
castanospermine did not interfere with surface expression of
the vesicular stomatitis virus G [29] or inﬂuenza virus hemag-
glutinin [30] proteins, suggesting that these molecules, like
delF508-CFTR are transported to the cell surface despite the
presence of glucosidase inhibitors.
Loss of function and/or accumulation of mutant proteins in
the ER leads to the development of numerous protein-misfold-
ing diseases [31]. Because the molecular mechanism of
C. Norez et al. / FEBS Letters 580 (2006) 2081–2086 2085retention of the mutant proteins associated with these diseases
may have (at least in part) in common the recognition of mu-
tant proteins by calnexin and retention in the ER, glucosidase
inhibitors might be valuable candidates for pharmacological
prevention of protein-misfolding diseases [31–34].
Miglustat is an orally bioavailable orphan drug approved in
Europe and USA for use in patients with type I Gaucher dis-
ease (Zavesca) [15]. Human studies show that miglustat is
well tolerated at 100 or 300 mg once or three times daily
[15]. Imino sugar therapy has also been proposed for other dis-
eases [16], like Fabry disease [35].
Partial correction of CFTR channel activity may have signif-
icant clinical impact. For example, with the G480C traﬃcking
mutant 8% of mature CFTR protein is associated to 40%
residual cAMP-stimulated chloride secretion in mice intestine
[25]. We found that treatment with miglustat restored in CF
mice 12% mature CFTR and 55% of WT chloride secre-
tion. This is in reasonable good agreement with the estimation
that 100% chloride secretion corresponds with 20% mature
CFTR [28].
In conclusion, we found that miglustat rescues partially the
abnormal processing of functional delF508-CFTR in human
epithelial airway, tracheal gland serous and pancreatic duct
cells as well as in intestinal cells of delF508 mice. The mecha-
nism of action involves, at least in part, the prevention of
delF508/calnexin interaction in the ER. Because miglustat is
a medicament prescribed in another orphan disease, it holds
a great promise not only for CF therapy but also for an
increasing number of protein-misfolding diseases.
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